Sigmoid Social

The Japan TimesJapan is expected to lower the price of lecanemab, an Alzheimer's drug, following a health ministry panel's report citing its low cost-effectiveness. <a href="https://www.japantimes.co.jp/news/2025/07/10/japan/science-health/lecanemab-price-cut/?utm_medium=Social&utm_source=mastodon" rel="nofollow noopener" translate="no" target="_blank">https://www.japantimes.co.jp/news/2025/07/10/japan/science-health/lecanemab-price-cut/?utm_medium=Social&utm_source=mastodon</a> <a href="https://mastodon.social/tags/japan" class="mention hashtag" rel="nofollow noopener" target="_blank">#japan</a> <a href="https://mastodon.social/tags/sciencehealth" class="mention hashtag" rel="nofollow noopener" target="_blank">#sciencehealth</a> <a href="https://mastodon.social/tags/lecanemab" class="mention hashtag" rel="nofollow noopener" target="_blank">#lecanemab</a> <a href="https://mastodon.social/tags/alzheimer039s" class="mention hashtag" rel="nofollow noopener" target="_blank">#alzheimer039s</a> <a href="https://mastodon.social/tags/medicine" class="mention hashtag" rel="nofollow noopener" target="_blank">#medicine</a> <a href="https://mastodon.social/tags/health" class="mention hashtag" rel="nofollow noopener" target="_blank">#health</a> <a href="https://mastodon.social/tags/dementia" class="mention hashtag" rel="nofollow noopener" target="_blank">#dementia</a>

Europe Says<a href="https://www.europesays.com/2232275/" rel="nofollow noopener" translate="no" target="_blank">https://www.europesays.com/2232275/</a> Japan to cut price of Alzheimer’s drug lecanemab <a href="https://pubeurope.com/tags/alzheimer" class="mention hashtag" rel="nofollow noopener" target="_blank">#alzheimer</a> <a href="https://pubeurope.com/tags/japan" class="mention hashtag" rel="nofollow noopener" target="_blank">#japan</a> <a href="https://pubeurope.com/tags/lecanemab" class="mention hashtag" rel="nofollow noopener" target="_blank">#lecanemab</a>

Gute Pillen – Schlechte PillenSchwellungen und Blutungen des Gehirns sind unerwünschte Wirkungen der Antikörper gegen <a href="https://mastodon.social/tags/Alzheimer" class="mention hashtag" rel="nofollow noopener" target="_blank">#Alzheimer</a>-<a href="https://mastodon.social/tags/Demenz" class="mention hashtag" rel="nofollow noopener" target="_blank">#Demenz</a> – und das bei eher geringem Nutzen. Dabei scheint die Bilanz für <a href="https://mastodon.social/tags/Donanemab" class="mention hashtag" rel="nofollow noopener" target="_blank">#Donanemab</a> schlechter zu sein als bei <a href="https://mastodon.social/tags/Lecanemab" class="mention hashtag" rel="nofollow noopener" target="_blank">#Lecanemab</a>. (€) <a href="https://gutepillen-schlechtepillen.de/antikoerper-gegen-alzheimer-wenig-nutzen-schwere-risiken/" rel="nofollow noopener" translate="no" target="_blank">https://gutepillen-schlechtepillen.de/antikoerper-gegen-alzheimer-wenig-nutzen-schwere-risiken/</a>

tagesschauEU-Kommission lässt neuartigen Alzheimer-Wirkstoff Lecanemab zuAnders als bisherige Therapien soll der Wirkstoff Lecanemab die Alzheimer-Krankheit verlangsamen. Als erstes Medikament dieser Art erhielt es nun die Zulassung der EU. Infrage kommt es allerdings nur für wenige Patienten.➡️ <a href="https://www.tagesschau.de/wissen/gesundheit/alzheimer-lecanemab-eu-100.html?at_medium=mastodon&at_campaign=tagesschau.de" rel="nofollow noopener" translate="no" target="_blank">https://www.tagesschau.de/wissen/gesundheit/alzheimer-lecanemab-eu-100.html?at_medium=mastodon&at_campaign=tagesschau.de</a><a href="https://ard.social/tags/Alzheimer" class="mention hashtag" rel="nofollow noopener" target="_blank">#Alzheimer</a> <a href="https://ard.social/tags/EU" class="mention hashtag" rel="nofollow noopener" target="_blank">#EU</a> <a href="https://ard.social/tags/Lecanemab" class="mention hashtag" rel="nofollow noopener" target="_blank">#Lecanemab</a>

The Japan TimesThe European Medicines Agency said Thursday that its committee evaluating medical products has recommended partial approval of sales of lecanemab to treat Alzheimer's disease. <a href="https://www.japantimes.co.jp/news/2024/11/15/japan/science-health/lecanemab-drug-switch-recommendation/" rel="nofollow noopener" translate="no" target="_blank">https://www.japantimes.co.jp/news/2024/11/15/japan/science-health/lecanemab-drug-switch-recommendation/</a> <a href="https://mastodon.social/tags/japan" class="mention hashtag" rel="nofollow noopener" target="_blank">#japan</a> <a href="https://mastodon.social/tags/sciencehealth" class="mention hashtag" rel="nofollow noopener" target="_blank">#sciencehealth</a> <a href="https://mastodon.social/tags/lecanemab" class="mention hashtag" rel="nofollow noopener" target="_blank">#lecanemab</a> <a href="https://mastodon.social/tags/alzheimer039s" class="mention hashtag" rel="nofollow noopener" target="_blank">#alzheimer039s</a> <a href="https://mastodon.social/tags/pharmaceuticals" class="mention hashtag" rel="nofollow noopener" target="_blank">#pharmaceuticals</a> <a href="https://mastodon.social/tags/nationalhealthcare" class="mention hashtag" rel="nofollow noopener" target="_blank">#nationalhealthcare</a> <a href="https://mastodon.social/tags/dementia" class="mention hashtag" rel="nofollow noopener" target="_blank">#dementia</a> <a href="https://mastodon.social/tags/medicine" class="mention hashtag" rel="nofollow noopener" target="_blank">#medicine</a> <a href="https://mastodon.social/tags/health" class="mention hashtag" rel="nofollow noopener" target="_blank">#health</a>

Helmholtz-GemeinschaftWir sprechen in der neuesten Resonator-Podcastfolge über den aktuellen Stand der Alzheimerforschung. Zu Gast ist Christian Haas vom <a href="https://social.bund.de/@dzne" class="u-url mention" rel="nofollow noopener" target="_blank">@dzne</a> und es geht auch um neue Medikamente.Ganze Sendung: <a href="https://resonator-podcast.de/2024/res207-zum-stand-der-alzheimerforschung/" rel="nofollow noopener" translate="no" target="_blank">https://resonator-podcast.de/2024/res207-zum-stand-der-alzheimerforschung/</a> <a href="https://helmholtz.social/tags/Alzheimer" class="mention hashtag" rel="nofollow noopener" target="_blank">#Alzheimer</a> <a href="https://helmholtz.social/tags/DZNE" class="mention hashtag" rel="nofollow noopener" target="_blank">#DZNE</a> <a href="https://helmholtz.social/tags/Lecanemab" class="mention hashtag" rel="nofollow noopener" target="_blank">#Lecanemab</a> <a href="https://helmholtz.social/tags/Podcast" class="mention hashtag" rel="nofollow noopener" target="_blank">#Podcast</a>

Scientific EuropeanLecanemab for Early Alzheimer’s Disease approved in the UK but refused in EU  Monoclonal antibodies (mAbs) lecanemab and donanemab have been approved forthe treatment of early Alzheimer’s disease in the UK and USA respectively........... <a href="https://toot.community/tags/Alzheimer" class="mention hashtag" rel="nofollow noopener" target="_blank">#Alzheimer</a>’sDisease <a href="https://toot.community/tags/Dementia" class="mention hashtag" rel="nofollow noopener" target="_blank">#Dementia</a> <a href="https://toot.community/tags/EarlyAlzheimer" class="mention hashtag" rel="nofollow noopener" target="_blank">#EarlyAlzheimer</a>’sDisease <a href="https://toot.community/tags/EU" class="mention hashtag" rel="nofollow noopener" target="_blank">#EU</a> <a href="https://toot.community/tags/Lecanemab" class="mention hashtag" rel="nofollow noopener" target="_blank">#Lecanemab</a> <a href="https://toot.community/tags/Monoclonalantibody" class="mention hashtag" rel="nofollow noopener" target="_blank">#Monoclonalantibody</a> <a href="https://toot.community/tags/onanemab" class="mention hashtag" rel="nofollow noopener" target="_blank">#onanemab</a> <a href="https://toot.community/tags/UK" class="mention hashtag" rel="nofollow noopener" target="_blank">#UK</a> <a href="https://toot.community/tags/usa" class="mention hashtag" rel="nofollow noopener" target="_blank">#usa</a> Umesh Prasad <a href="https://www.scientificeuropean.co.uk/medicine/lecanemab-for-early-alzheimers-disease-approved-in-the-uk-but-refused-in-eu/" rel="nofollow noopener" translate="no" target="_blank">https://www.scientificeuropean.co.uk/medicine/lecanemab-for-early-alzheimers-disease-approved-in-the-uk-but-refused-in-eu/</a>

Kriszta Satori<a href="https://journa.host/tags/Lecanemab" class="mention hashtag" rel="nofollow noopener" target="_blank">#Lecanemab</a> : First drug to slow <a href="https://journa.host/tags/Alzheimer" class="mention hashtag" rel="nofollow noopener" target="_blank">#Alzheimer</a> ’s can be prescribed but too costly for NHS - NICE says the benefits “are too small to justify the costs”. <a href="https://www.bbc.co.uk/news/articles/c75nry66y52o" rel="nofollow noopener" translate="no" target="_blank">https://www.bbc.co.uk/news/articles/c75nry66y52o</a>

LupposofiA long-awaited AlzForum's take on the news that ApoE4 homozygotism means in fact an AD pathology (though not necessarily dementia before death), <a href="https://www.alzforum.org/news/research-news/do-two-apoe4-alleles-always-mean-alzheimers" rel="nofollow noopener" translate="no" target="_blank">https://www.alzforum.org/news/research-news/do-two-apoe4-alleles-always-mean-alzheimers</a>The comments-section gives a glimpse of some of the trenchlines regarding the treatment of dementia, but I guess the prevention-camp has only just been strirred up from their Sleeping Beauty's slumber.I, as an example, still have only a 1 % measured risk of acquiring AD, according to some widely used screens, and no "preventable risk factors" except maybe age. Too bad, my genetic inheritance seems to have been enough to skew the Amyloid-Beta balance early on. Luckily, I was recruited to the aducanumab-study for four years (a precursor of lecanemab with more severe side-effects), and probably got some more years to be able to think things like these.<a href="https://mementomori.social/tags/alzheimer" class="mention hashtag" rel="nofollow noopener" target="_blank">#alzheimer</a> <a href="https://mementomori.social/tags/research" class="mention hashtag" rel="nofollow noopener" target="_blank">#research</a> <a href="https://mementomori.social/tags/medical" class="mention hashtag" rel="nofollow noopener" target="_blank">#medical</a> <a href="https://mementomori.social/tags/APOE4" class="mention hashtag" rel="nofollow noopener" target="_blank">#APOE4</a> <a href="https://mementomori.social/tags/alzForum" class="mention hashtag" rel="nofollow noopener" target="_blank">#alzForum</a> <a href="https://mementomori.social/tags/dementia" class="mention hashtag" rel="nofollow noopener" target="_blank">#dementia</a> <a href="https://mementomori.social/tags/ad" class="mention hashtag" rel="nofollow noopener" target="_blank">#ad</a> <a href="https://mementomori.social/tags/alzheimers" class="mention hashtag" rel="nofollow noopener" target="_blank">#alzheimers</a> <a href="https://mementomori.social/tags/amyloid" class="mention hashtag" rel="nofollow noopener" target="_blank">#amyloid</a> <a href="https://mementomori.social/tags/lecanemab" class="mention hashtag" rel="nofollow noopener" target="_blank">#lecanemab</a> <a href="https://mementomori.social/tags/aducanumab" class="mention hashtag" rel="nofollow noopener" target="_blank">#aducanumab</a> <a href="https://mementomori.social/tags/prevention" class="mention hashtag" rel="nofollow noopener" target="_blank">#prevention</a> <a href="https://mementomori.social/tags/cure" class="mention hashtag" rel="nofollow noopener" target="_blank">#cure</a>

Recent searches

Search options

Administered by:

Server stats:

#lecanemab